NLS Pharmaceutics Ltd. Announces Closing of US$4.4 Million Registered Start Investing Direct Offering

ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorder, today announced the closing of its previously announced registered direct offering with health-care focused institutional investors alongside participation from the Company’s Chairman of the Board of Directors, Ronald Hafner, for the purchase and sale of 4,200,000 of the Company’s common shares (or common share equivalents) at a purchase price of $1.